Epkinly
Payments companies reported to CMS as associated with Epkinly. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Epkinly, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Epkinly
These are the largest totals companies reported as associated with Epkinly. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Tara Graff | Clive, IA | Medical Oncology | $148,765.56 |
| Suzanne Fanning | Greenville, SC | Hematology & Oncology | $120,798.36 |
| Ralph Boccia | Bethesda, MD | Hematology & Oncology | $115,394.99 |
| Hakan Kaya | Spokane, WA | Medical Oncology | $103,472.19 |
| Jonathan Abbas | Nashville, TN | Hematology & Oncology | $92,930.59 |
| Mark Fesler | Saint Louis, MO | Hematology & Oncology | $90,889.75 |
| Habte Yimer | Tyler, TX | Hematology & Oncology | $90,305.66 |
| Moshe Levy | Dallas, TX | Medical Oncology | $85,146.23 |
| Raghuveer Ranganathan | Los Angeles, CA | Hematology & Oncology | $80,126.61 |
| Joshua Brody | New York, NY | Medical Oncology | $69,354.06 |
Prescribed Epkinly?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.